{"id":15055,"date":"2021-06-07T08:50:49","date_gmt":"2021-06-07T06:50:49","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15055"},"modified":"2024-12-11T22:10:45","modified_gmt":"2024-12-11T21:10:45","slug":"ixazomib-daratumumab-et-dexamethasone-en-1ere-ligne-pour-les-patients-fragiles","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/ixazomib-daratumumab-et-dexamethasone-en-1ere-ligne-pour-les-patients-fragiles\/","title":{"rendered":"Ixazomib, daratumumab et dexam\u00e9thasone en 1re ligne pour les patients fragiles"},"content":{"rendered":"

R\u00e9f. : HematoStat.net ; 2 (2) : R15<\/p>\n

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon <\/span><\/i>143 Study<\/span><\/strong><\/div>\n
<\/div>\n
Stege, C. A. M. and al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. J. Clin. Oncol. JCO.20.03143 (2021) doi:10.1200\/JCO.20.03143.<\/span><\/i><\/a><\/div>\n
<\/div>\n
\n

R\u00e9sum\u00e9 :<\/strong><\/h3>\n

Peu de donn\u00e9es existent quant au traitement optimal du my\u00e9lome multiple nouvellement diagnostiqu\u00e9s du sujet fragile. Le groupe HOVON rapporte leur \u00e9tude de phase 2 \u00e9valuant l\u2019efficacit\u00e9 de la combinaison ixazomib, daratumumab et dexam\u00e9thasone chez 65 patients jug\u00e9s fragiles selon l\u2019index de l\u2019IMWG. Le taux de r\u00e9ponse et la survie sans progression \u00e9tait de 78 % et 13,8 mois, respectivement (suivi : 22,9 mois).<\/p>\n

Dans nos pratiques :<\/strong><\/h3>\n

Combinaison \u00e0 priori peu toxique sur le papier, 51 % des patients ont interrompus pr\u00e9matur\u00e9ment l\u2019induction. En cause notamment, le poids de certains effets secondaires de faible grade mais avec un retentissement sur la qualit\u00e9 de vie comme la neuropathie p\u00e9riph\u00e9rique. Une premi\u00e8re \u00e9tude qui a le m\u00e9rite de proposer un standard d\u2019induction moderne \u00e0 destination des patients les plus fragiles.<\/p>\n

Le regard du statisticien : <\/strong><\/h3>\n

Un essai de phase II classique et bien document\u00e9, qui n\u00e9cessite toutefois de devoir de se pencher dans les Data supplement <\/i>pour les analyses plus pouss\u00e9es sur les crit\u00e8res secondaires. Ce type d\u2019\u00e9tude pose la question de savoir s\u2019il ne faudrait pas utiliser l\u2019arr\u00eat d\u2019un traitement comme \u00e9v\u00e9nement \u00e0 part enti\u00e8re pour permettre son \u00e9valuation.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":14610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[78,79,80,81,82],"ppma_author":[456],"class_list":["post-15055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-daratumumab","tag-data-supplement","tag-dexamethasone","tag-ixazomib","tag-patients-fragiles","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15055"}],"version-history":[{"count":2,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15055\/revisions"}],"predecessor-version":[{"id":18312,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15055\/revisions\/18312"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15055"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}